ClinicalTrials.gg
CompletedNCT03290365Updated Jul 13, 2021

The Combination Effect of Platelet-rich Plasma and Hyaluronic Acid for Knee Osteoarthritis

An interventional study of platelet rich plasma + Hyaluronic acid and platelet rich plasma + normal saline in Knee Osteoarthritis, sponsored by Tri-Service General Hospital. Completed at 1 site in Taiwan. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by Tri-Service General Hospital · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing platelet rich plasma in Osteoarthritis, Knee — 3 open to participants now, 4 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis, Knee.

Enrollment
29th of 43
46 · median 60
Started
2018
with 2 others
No phase
14 of 43
1 open now
Registered
19th of 43
by date

Among the 43 studies testing platelet rich plasma in Osteoarthritis, Knee, this one is the 29th largest by enrollment, is one of 3 that started in 2018, is one of 14 with no phase, and was the 19th registered.

Osteoarthritis, Knee

3,296 studies on the registry are indexed under Osteoarthritis, Knee; 625 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 43 studies testing platelet rich plasma in Osteoarthritis, Knee are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing platelet rich plasma in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

Although platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for osteoarthritis of knee (OA knee), the combined effect of PRP with HA was not clear so far. Hence, investigator assess a prospective randomized double-blind controlled trial.

Read the detailed description

Patients with single or bilateral OA knee will be enrolled and randomized into intervention and control group. One dose of PRP is applied into both groups. One week later, one dose of HA is injected in intervention group and one dose of normal saline is injected in control group. Outcome measurements included visual analog scale (VAS)、Lequesne's severity index、Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)、balance test (Biodex) and analysis of synovial fluid at different follow-up frame (1st month, 3rd month, 6th month and 1 year after treatment).

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Platelet rich plasma
  • Osteoarthritis of knee
  • Hyaluronic acid
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 50 to 75 y/o.
  2. Alert consciousness
  3. Symptom of knee osteoarthritis persist at least 6 months and stage I to III scored by Ahlbäck grading system
  4. The pain score measured by VAS at least 4 points

Exclusion criteria

Exclusion Criteria:

  1. Has received hyaluronic acid, PRP or injection within 6 months
  2. Has received NSAIDs or steroid within one week
  3. Tumor or surrounding the knee joint
  4. Has received total knee replacement, major surgery in knee, rheumatoid arthritis
  5. Patient who cant tolerance the balance test.
  6. Thrombocytopenia or coagulopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Platelet rich plasma + Hyaluronic acid

    Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.

    Drug: platelet rich plasma + Hyaluronic acid

  • Placebo comparator
    Platelet rich plasma + normal saline

    Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.

    Drug: platelet rich plasma + normal saline

Interventions

  • Drugplatelet rich plasma + Hyaluronic acid

    Drug pages: Platelet rich plasma · Hyaluronic Acid

    Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.

  • Drugplatelet rich plasma + normal saline

    The normal salin as the placebo intervention was injection control group.

06

What researchers measure

Primary outcomes

  1. Change from baseline in severity of symptoms and functional status on 1st month, 3rd month, 6th month and one year after injection.

    Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to measure the symptoms and functional status before treatment and multiple time frame after treatment. Both subscales has the scores ranged from 1 to 5 for each item and a higher score indicating more severe of symptom or impaired functional status.

    Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.

Secondary outcomes

  1. Change from baseline in severity of symptoms and functional status on 1st month, 3rd month, 6th month and one year after injection.

    Using the Lequesne's severity index to measure the symptoms and functional status before treatment and multiple time frame after treatment. A higher score indicate more severe.

    Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.

  2. Change from baseline of pain on 1st month, 3rd month, 6th month and one year after injection.

    Using the Visual analog scale (VAS) to measure the pain scale before treatment and multiple time frame after treatment. The score ranging from 10 (remarkable pain) to 0 (no pain).

    Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.

  3. Change from baseline in balance function on 1st month, 3rd month, 6th month and one year after injection.

    Using the balance test (Biodex) to measure the balance function before treatment and multiple time frame after treatment.

    Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.

  4. Change from baseline in analysis of synovial fluid on 6th month and one year after injection.

    The synovial fluid is aspirated to measure the parameters before treatment and multiple time frame after treatment.

    Time frame: Pre-treatment, 6th month and one year after injection.

07

Study locations

1 site
  • Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
    Taipei, Neihu District 886, Taiwan
08

References and documents

Publications

  • Abate M, Verna S, Schiavone C, Di Gregorio P, Salini V. Efficacy and safety profile of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results). Eur J Orthop Surg Traumatol. 2015 Dec;25(8):1321-6. doi: 10.1007/s00590-015-1693-3. Epub 2015 Sep 24. PubMed 26403468 ↗
  • Lana JF, Weglein A, Sampson SE, Vicente EF, Huber SC, Souza CV, Ambach MA, Vincent H, Urban-Paffaro A, Onodera CM, Annichino-Bizzacchi JM, Santana MH, Belangero WD. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med. 2016 Nov 29;12(2):69-78. doi: 10.46582/jsrm.1202011. eCollection 2016. PubMed 28096631 ↗
  • Chen SH, Kuan TS, Kao MJ, Wu WT, Chou LW. Clinical effectiveness in severe knee osteoarthritis after intra-articular platelet-rich plasma therapy in association with hyaluronic acid injection: three case reports. Clin Interv Aging. 2016 Sep 8;11:1213-1219. doi: 10.2147/CIA.S114795. eCollection 2016. PubMed 27660427 ↗
  • Dallari D, Stagni C, Rani N, Sabbioni G, Pelotti P, Torricelli P, Tschon M, Giavaresi G. Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. Am J Sports Med. 2016 Mar;44(3):664-71. doi: 10.1177/0363546515620383. Epub 2016 Jan 21. PubMed 26797697 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2021, 41 months.

Of 1,113 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 41 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 21, 2017
StartActual
Jan 10, 2018
Primary completionActual
Jul 1, 2021
CompletionActual
Jul 1, 2021
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03290365
Responsible party
Yung-Tsan Wu (Attending Physician, Tri-Service General Hospital) — Principal investigator
First posted
Sep 21, 2017
Start date
Jan 10, 2018
Primary completion
Jul 1, 2021
Completion
Jul 1, 2021
Last update
Jul 13, 2021

Study contacts

Yung-Tsan Wu, MD
principal investigator · Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, National Defense Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Platelet rich plasma · Hyaluronic Acid

Start the discussion